Genelux (GNLX) Amortization - Intangibles (2022 - 2023)

Genelux (GNLX) recorded quarterly Amortization - Intangibles of $649000.0 in Q1 2023, up 490.0% quarter-over-quarter from $110000.0 in Q4 2022.

Genelux (GNLX) Amortization - Intangibles (2022 - 2023) Analysis & Trends

Genelux's Amortization - Intangibles history runs 2 years deep, the most recent figure standing at $649000.0 for Q1 2023.

In Q1 2023, Amortization - Intangibles changed N/A year-over-year to $649000.0; the TTM figure through Dec 2023 stood at $649000.0 (changed N/A YoY), while the FY2023 annual figure was $649000.0, up 151.55% from the prior year.
Amortization - Intangibles was $649000.0 for Q1 2023 at Genelux, up from $110000.0 in the prior quarter.
In the past five years, Amortization - Intangibles ranged from a high of $649000.0 in Q1 2023 to a low of $49000.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Genelux	129.36 Mn	129.36 Mn	-

Download Data